I am two days through my 4 day course in Oral and Myofunctional Therapy and I am convinced that Oral Myofunctional Therapy will increase health and wellness in many patients.
I spent three days last fall in California at the Academy of Applied Myofunctional Sciences and was blown away by the science. My wife Anna and I are now becoming knowledgable about using this information to improve the lives of my patients.
This is especially true in patients with sleep apnea (especially children) While it is not currently a cure I t is safe to concluded that myofunctional therapy is an excellent adjunct therapy for treating sleep apnea.
Te DNA Appliance has been shown in clinica cases to cure sleep apnea and combining Myofunctional Therapy and the DNA Appliance is a given.
This new publication on Myofunctional Therapy concludes based on Meta-Analysis that “Current literature demonstrates that myofunctional therapy decreases apnea-hypopnea index by approximately 50% in adults and 62% in children. Lowest oxygen saturations, snoring, and sleepiness outcomes improve in adults. Myofunctional therapy could serve as an adjunct to other obstructive sleep apnea treatments.
PubMed Abstract below:
Sleep. 2015 May 1;38(5):669-75. doi: 10.5665/sleep.4652.
Myofunctional Therapy to Treat Obstructive Sleep Apnea: A Systematic Review and Meta-analysis.
Camacho M1, Certal V2, Abdullatif J3, Zaghi S4, Ruoff CM1, Capasso R5, Kushida CA1.
To systematically review the literature for articles evaluating myofunctional therapy (MT) as treatment for obstructive sleep apnea (OSA) in children and adults and to perform a meta-analysis on the polysomnographic, snoring, and sleepiness data.
Web of Science, Scopus, MEDLINE, and The Cochrane Library.
The searches were performed through June 18, 2014. The Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) statement was followed.
Nine adult studies (120 patients) reported polysomnography, snoring, and/or sleepiness outcomes. The pre- and post-MT apneahypopnea indices (AHI) decreased from a mean ± standard deviation (M ± SD) of 24.5 ± 14.3/h to 12.3 ± 11.8/h, mean difference (MD) -14.26 [95% confidence interval (CI) -20.98, -7.54], P < 0.0001. Lowest oxygen saturations improved from 83.9 ± 6.0% to 86.6 ± 7.3%, MD 4.19 (95% CI 1.85, 6.54), P = 0.0005. Polysomnography snoring decreased from 14.05 ± 4.89% to 3.87 ± 4.12% of total sleep time, P < 0.001, and snoring decreased in all three studies reporting subjective outcomes. Epworth Sleepiness Scale decreased from 14.8 ± 3.5 to 8.2 ± 4.1. Two pediatric studies (25 patients) reported outcomes. In the first study of 14 children, the AHI decreased from 4.87 ± 3.0/h to 1.84 ± 3.2/h, P = 0.004. The second study evaluated children who were cured of OSA after adenotonsillectomy and palatal expansion, and found that 11 patients who continued MT remained cured (AHI 0.5 ± 0.4/h), whereas 13 controls had recurrent OSA (AHI 5.3 ± 1.5/h) after 4 y. CONCLUSION: Current literature demonstrates that myofunctional therapy decreases apnea-hypopnea index by approximately 50% in adults and 62% in children. Lowest oxygen saturations, snoring, and sleepiness outcomes improve in adults. Myofunctional therapy could serve as an adjunct to other obstructive sleep apnea treatments. © 2015 Associated Professional Sleep Societies, LLC.